Vancomycin-hydrochloride - Bacterial 抑制劑 - 生命科學(xué)試劑 - MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEVancomycin hydrochlorideCat. No.: HY-17362CAS No.: 1404-93-9分式: CHClNO分量: 1485.72作靶點(diǎn): Bacterial; Autophagy作通路: Anti-infection; Autophagy儲(chǔ)存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) H2O : 33.33

2、mg/mL (22.43 mM; Need ultrasonic)DMSO : 24 mg/mL (16.15 mM; Need ultrasonic and warming)Mass Solvent1 mg 5 mg 10 mg Concentration制備儲(chǔ)備液1 mM 0.6731 mL 3.3654 mL 6.7307 mL5 mM 0.1346 mL 0.6731 mL 1.3461 mL10 mM 0.0673 mL 0.3365 mL 0.6731 mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲(chǔ)備液，并請(qǐng)注意儲(chǔ)備液的保存式和期限。體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥式選擇

3、適當(dāng)?shù)娜芙獍?，配制前?qǐng)先配制澄的儲(chǔ)備液，再依次添加助溶劑(為保證實(shí)驗(yàn)結(jié)果的可靠性，體內(nèi)實(shí)驗(yàn)的作液，建議您現(xiàn)現(xiàn)配，當(dāng)天使；澄的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；以下溶劑前的百分 指該溶劑在您配制終溶液中的體積占)：1. 請(qǐng)依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (1.68 mM); Clear solution2. 請(qǐng)依序添加每種溶劑： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.5 mg/mL (1.68 mM); Clear sol

4、ution3. 請(qǐng)依序添加每種溶劑： 10% DMSO 90% corn oil1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemESolubility: 2.5 mg/mL (1.68 mM); Clear solutionBIOLOGICAL ACTIVITY物活性 Vancomycin hydrochloride于治療細(xì) 感染 (bacterial) 的抗素。 它通過抑制易感細(xì)的細(xì)胞壁合成的第階段起作。 Vancomycin還改變細(xì)胞膜的滲透性并選擇性地抑制核糖核酸的合成。IC50 & Target Bacterial 1體外研究 Vanco

5、mycin is a large glycopeptide compound with a molecular weight of 1450 Da 1. Vancomycin is aunique glycopeptide structurally unrelated to any currently available antibiotic. It also has a unique mode ofaction inhibiting the second stage of cell wall synthesis of susceptible bacteria. Vancomycin is a

6、ctive againsta large number of species of Gram-positive bacteria, such as Staphylococcus aureus, Staph. epidermidis,Str. agalactiae, Str. bovis, Str. mutans, viridans streptococci, enterococci 2.體內(nèi)研究 Vancomycin is administered intravenously, with a standard infusion time of at least 1 h, to minimize

7、 infusion-related adverse effects. Subjects with normal creatinine clearance, vancomycin has an -distribution phaseof 30 min to 1 h and a -elimination half-life of 6-12 h. The volume of distribution is 0.41 L/kg. The binding ofvancomycin to protein ranges from 10% to 50%. Factors that affect the ove

8、rall activity of vancomycin includeits tissue distribution, inoculum size, and protein-binding effects 1. Vancomycin treatment of infected mice isassociated with improved clinical, diarrhea, and histopathology scores and survival during treatment 3.PROTOCOLAnimal Mice: One set of experiments is perf

9、ormed in which infected mice are treated with vancomycin (50 mg/kg)Administration 3 daily for 1, 2, 3, or 5 days and are observed for 21 days postinfection or with vancomycin (20 mg/kg) daily foreither 5 or 10 days and monitoring for 15 days postinfection 3.MCE has not independently confirmed the ac

10、curacy of these methods. They are for reference only.戶使本產(chǎn)品發(fā)表的科研獻(xiàn) Chemosphere. 2019 Mar.See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Rybak MJ, et al. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2006 Jan 1;42 Suppl 1:S35-9.2. Watanakunako

11、rn C, et al. Mode of action and in-vitro activity of vancomycin. J Antimicrob Chemother. 1984 Dec;14 Suppl D:7-18.3. Warren CA, et al. Vancomycin treatments association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence ofClostridium difficile infection in mice. Antimicrob Agents Chemother. 2013 Feb;57(2):689-96.McePdfHeight2/2 Master of Small Molecules 您邊的抑制劑師www.MedChemECaution: Product has